Cargando…

P1429: IN VITRO COMPARISON OF THE EFFECTS OF INCLACUMAB VS CRIZANLIZUMAB ON REDUCING ENDOTHELIAL ADHESION OF RED BLOOD CELLS IN STANDARDIZED MICROFLUIDIC PLATFORM

Detalles Bibliográficos
Autores principales:	Federici, Chiara, Sertel, Seniye, Braxton, Samantha, Combs, Gabrielle, Sphen, Madelyn, Ophein, Kara, Kovshovik, Pavel, Zak, John, Geng, Xin, Gurkan, Umut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430623/ http://dx.doi.org/10.1097/01.HS9.0000972600.79286.5a

Ejemplares similares

P1439: EPELEUTON, A NOVEL SYNTHETIC Ω-3 FATTY ACID, REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS UNDER PHYSIOLOGICAL FLOW CONDITIONS
por: Hamza, Moayed, et al.
Publicado: (2023)

P-030: CRIZANLIZUMAB REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SCD PATIENTS IN STANDARDIZED MICROFLUIDIC PLATFORM: IN VITRO TECHNOLOGY ASSESSMENT
por: C., FEDERICI, et al.
Publicado: (2022)

First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin
por: Schmitt, Christophe, et al.
Publicado: (2015)

S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE
por: Tarasev, M, et al.
Publicado: (2022)

Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
por: Gue, Ying X., et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series
por: Idowu, Modupe, et al.
Publicado: (2023)

Chinese translation norms for 1,429 English words
por: Wen, Yun, et al.
Publicado: (2016)

Impact of Crizanlizumab on Acute Medical Care Utilization in the Height of the COVID-19 Pandemic
por: Rao, Shivani, et al.
Publicado: (2021)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

1429. Temperature and Humidity Variations in the Operating Room: A Risk Assessment
por: Usiak, Shauna, et al.
Publicado: (2023)

A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease
por: Mayer, Christina Lourdes, et al.
Publicado: (2023)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial
por: Stähli, Barbara E., et al.
Publicado: (2016)

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
por: Leucker, Thorsten M., et al.
Publicado: (2021)

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

The P-Type ATPase PA1429 Regulates Quorum-Sensing Systems and Bacterial Virulence
por: Zhang, Yani, et al.
Publicado: (2017)

1429 Nasopharyngeal Carriage of Potential Bacterial and Viral Pathogens in Hospitalized Patients with Respiratory Symptoms
por: Asis, Esmeralda, et al.
Publicado: (2014)

KIAA1429 regulates alternative splicing events of cancer-related genes in hepatocellular carcinoma
por: Liu, Zhao-chen, et al.
Publicado: (2022)

KIAA1429 promotes infantile hemangioma regression by facilitating the stemness of hemangioma endothelial cells
por: Wang, Luying, et al.
Publicado: (2023)

5572697 TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, B., et al.
Publicado: (2023)

Heterogeneous Red Blood Cell Adhesion and Deformability in Sickle Cell Disease
por: Alapan, Yunus, et al.
Publicado: (2014)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

P1486: TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, B., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Sa1429: CLINICAL AND PREDICTIVE FACTORS ASSOCIATED WITH NEED FOR TRANSJUGULAR PORTOSYSTEMIC SHUNT (TIPS) REVISION
por: Healey, Marcus A., et al.
Publicado: (2022)

m6A ‘writer’ KIAA1429 regulates the proliferation and migration of endothelial cells in atherosclerosis
por: Rong, Jian, et al.
Publicado: (2022)

The biological function of m6A methyltransferase KIAA1429 and its role in human disease
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma
por: Tan, Kezhe, et al.
Publicado: (2023)

KIAA1429 facilitates progression of hepatocellular carcinoma by modulating m6A levels in HPN
por: Meng, Yu, et al.
Publicado: (2023)

S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
por: Mayer, C, et al.
Publicado: (2022)

Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction
por: Bickel, Fabian, et al.
Publicado: (2022)

P1441: REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

Integrating deep learning with microfluidics for biophysical classification of sickle red blood cells adhered to laminin
por: Praljak, Niksa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjt87ili52gvstnmjdoe5m4bfn